ClinConnect ClinConnect Logo
Search / Trial NCT06554470

Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy

Launched by TANTA UNIVERSITY · Aug 14, 2024

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two different ways to give a medication called methotrexate for treating uterine ectopic pregnancy, a condition where a pregnancy occurs outside the uterus. The researchers want to find out if giving methotrexate directly to the affected area (local) works better than giving it through the bloodstream (systemic) in helping the body clear the pregnancy tissue. They will also look at how long it takes for a hormone called beta-hCG to return to normal levels and whether participants need any additional treatments.

To be eligible for this study, women aged 20 to 40 with a uterine ectopic pregnancy that is less than 9 weeks along and meets certain criteria can participate. This includes having a small embryo size and specific hormone levels. Participants can expect to receive either the local or systemic treatment and will be monitored for their progress. It’s important to note that women with certain health conditions, such as severe bleeding or previous cancer, cannot join the study. This trial is currently recruiting participants, so if you or someone you know fits the criteria, it could be an opportunity to contribute to important medical research.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Age from 20 to 40 years.
  • Women with uterine ectopic pregnancy (interstitial pregnancy, cervical pregnancy, or cesarean scar pregnancy).
  • Gestational age is less than 9 weeks, the embryo size is smaller than 10 mm, and the serum beta-human chorionic gonadotropin (β-hCG) levels are less than 10,000 mIU/mL.
  • Exclusion Criteria:
  • Patients with basal beta hCG levels less than 1500 mIU/Ml.
  • Any contraindications to MTX as a hepatic disorder, renal disorder and thrombocytopenia
  • Diabetes mellitus.
  • Severe vaginal bleeding or hemodynamic changes or hemoperitoneum.
  • History of cancer.
  • Ascites.
  • Pleural effusion.

About Tanta University

Tanta University is a prestigious academic institution located in Egypt, dedicated to advancing medical research and education. As a clinical trial sponsor, Tanta University leverages its extensive resources and expertise to conduct innovative research initiatives aimed at improving health outcomes. The university collaborates with a network of healthcare professionals, researchers, and institutions to facilitate rigorous clinical trials across various medical disciplines. Committed to ethical standards and scientific integrity, Tanta University strives to contribute to the global body of knowledge while fostering the next generation of medical professionals.

Locations

Tanta, El Gharbia, Egypt

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported